This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”

Spinraza (nusinersen)
General Description:
Spinraza (nusinersen) is an antisense oligonucleotide (ASO) developed for the treatment of Spinal Muscular Atrophy (SMA) — a rare and often fatal hereditary (genetic) disease that causes progressive muscle weakness and wasting due to the loss of motor neurons controlling movement.
SMA is primarily caused by mutations in the chromosome 5q region, leading to a deficiency of the survival motor neuron (SMN) protein. Spinraza works by modifying the synthesis of the SMN protein to increase the production of full-length, functional SMN, thereby supporting the survival and maintenance of motor neurons. This helps slow disease progression and improve motor function in patients.
Disease Indications:
Spinal Muscular Atrophy (SMA)
Manufacturer:
Biogen Idec Ltd
Usage:
Intrathecal Injection
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Therapeutic Goods Administration (TGA)
• Medsafe (New Zealand)
Package:
• Single vial: 1 vial of 12 mg/5 mL
Shipping:
Cold Chain Shipping
Spinraza contains temperature-sensitive biological ingredients that must be protected from heat, light, and improper handling. To maintain product stability and therapeutic efficacy, Spinraza is shipped under cold chain delivery conditions using specialized medical couriers equipped with temperature-regulated packaging and vehicles.
Although cold chain shipping may incur higher costs than standard delivery methods, it ensures that Spinraza remains safe, stable, and fully effective for patient administration.



